Agrimonia pilosa for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 26 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Agrimonia pilosa may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed Agrimonia pilosa in detail.

Studies suggesting benefit with Agrimonia pilosa

Huang et al., Magnetic Bead‐Based Ligand Fishing Identifies SARS‐CoV‐2 Main Protease Inhibitors From Reynoutria japonica, Chemistry & Biodiversity, doi:10.1002/cbdv.71722

ABSTRACT Traditional Chinese medicines (TCMs) are rich sources of structurally diverse bioactive compounds, yet rapid identification of protease inhibitors from complex botanical matrices remains challenging. Here, a magnetic bead‐based affinity‐fishing platform coupled with UPLC‐Q‐Exactive‐Orbitrap‐MS/MS was applied to identify SARS‐CoV‐2 main protease (M pro ) inhibitors from Reynoutria japonica . The crude ethanolic extract inhibited M pro with an IC 50 of 44.92 ± 2.31 µg/mL. M pro ‐functionalized magnetic beads enriched eight constituents, which were identified by high‐resolution mass spectrometry and evaluated using a FRET‐based inhibition assay. Six compounds showed concentration‐dependent activity, with resveratrol being the most potent (IC 50 = 34.01 ± 1.67 µmol/L), followed by glycitein, genistein, emodin, apigenin‐7‐ O ‐glucoside, and biochanin A. HPLC‐DAD further quantified the principal active constituents. Molecular docking suggested interactions with residues in the Mpro substrate‐binding pocket, while network pharmacology predicted associations with host‐related targets involving IL6, TNF, and AKT1. Overall, this workflow enables efficient enrichment, structural identification, and functional prioritization of M pro ‐inhibitory constituents from complex botanical extracts, providing a practical strategy for target‐directed natural product discovery.

El-Morsi et al., Bioactive galloylquinic acids from Copaifera lucens as dual inhibitors of SARS-CoV-2 Spike and RdRp proteins, Scientific Reports, doi:10.1038/s41598-025-25217-8

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Despite the fact that coronavirus disease 2019 (COVID-19) treatment and management are now considerably regulated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still one of the leading causes of death in 2022. The availability of COVID-19 vaccines, FDA-approved antivirals, and monoclonal antibodies in low-income countries still poses an issue to be addressed. Natural products, particularly traditional Chinese medicines (TCMs) and medicinal plant extracts (or their active component), have challenged the dominance of drug repurposing and synthetic compound libraries in COVID-19 therapeutics. Their abundant resources and excellent antiviral performance make natural products a relatively cheap and readily available alternative for COVID-19 therapeutics. Here, we deliberately review the anti-SARS-CoV-2 mechanisms of the natural products, their potency (pharmacological profiles), and application strategies for COVID-19 intervention. In light of their advantages, this review is intended to acknowledge the potential of natural products as COVID-19 therapeutic candidates.